A novel mechanism of imeglimin-mediated insulin secretion via the cADPR-TRP channel pathway.

ABSTRACT:

Aims/introduction

Imeglimin is a novel oral hypoglycemic agent that improves blood glucose levels through multiple mechanisms of action including the enhancement of glucose-stimulated insulin secretion (GSIS), however, the details of this mechanism have not been clarified. In the process of GSIS, activation of the transient receptor potential melastatin 2 (TRPM2) channel, a type of non-selective cation channel (NSCCs) in β-cells, promotes plasma membrane depolarization. The present study aimed to examine whether imeglimin potentiates GSIS via the TRPM2 channel in β-cells.

Materials and methods

Pancreatic islets were isolated by collagenase digestion from male wild-type and TRPM2-knockout (KO) mice. Insulin release and nicotinamide adenine dinucleotide (NAD⁺ ) prod

SUBMITTER: Funazaki S 

PROVIDER: S-EPMC8756313 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature